|
|
Volumn 11, Issue 8, 2010, Pages 701-
|
|
Bad month for cancer care in the UK
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CAPECITABINE;
CISPLATIN;
EPIRUBICIN;
ERLOTINIB;
EVEROLIMUS;
FLUOROURACIL;
IMATINIB;
MIFAMURTIDE;
OFATUMUMAB;
PEMETREXED;
TRABECTEDIN;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
BREAST CANCER;
CANCER SURVIVAL;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG MANUFACTURE;
EDITORIAL;
FUNDING;
GASTROINTESTINAL STROMAL TUMOR;
GOVERNMENT;
HUMAN;
KIDNEY CARCINOMA;
LICENSING;
LUNG NON SMALL CELL CANCER;
MAINTENANCE THERAPY;
MALIGNANT NEOPLASTIC DISEASE;
OSTEOSARCOMA;
OVARY CANCER;
OVERALL SURVIVAL;
PATIENT CARE;
PATIENT RIGHT;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
RELAPSE;
STOMACH CANCER;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS;
COST CONTROL;
DISEASE-FREE SURVIVAL;
DRUG APPROVAL;
DRUG COSTS;
GREAT BRITAIN;
HEALTH SERVICES ACCESSIBILITY;
HUMANS;
NEOPLASMS;
STATE MEDICINE;
|
|
EID: 77955247296
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(10)70190-X Document Type: Editorial |
|
Times cited : (1)
|
|
References (0)
|